Repligen (RGEN) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Repligen (NASDAQ: RGEN):

• 2/28/2026 – Repligen was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/25/2026 – Repligen had its “overweight” rating reaffirmed by KeyCorp.
• 2/25/2026 – Repligen had its price target lowered by UBS Group AG from $200.00 to $195.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Repligen had its price target lowered by Barclays PLC from $200.00 to $175.00. They now have an “overweight” rating on the stock.
• 2/25/2026 – Repligen had its price target lowered by Wells Fargo & Company from $190.00 to $180.00. They now have an “overweight” rating on the stock.
• 2/17/2026 – Repligen was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 2/7/2026 – Repligen was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/30/2026 – Repligen was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 1/16/2026 – Repligen had its price target raised by UBS Group AG from $190.00 to $200.00. They now have a “buy” rating on the stock.
• 1/12/2026 – Repligen was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.

Insider Activity

In related news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by corporate insiders.

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.